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A Thyroid Hormone-Independent Molecular Fingerprint
of 3,5-Diiodothyronine Suggests a Strong Relationship
with Coffee Metabolism in Humans
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Georg Brabant,6 Henry Vo¨lzke,2,7,8 Anna Artati,9 Jerzy Adamski,9–12 Uwe Vo¨lker,2,13
Matthias Nauck,1,2 Nele Friedrich,1,2 and Georg Homuth13
Background: In numerous studies based predominantly on rodent models, administration of 3,5-diiodo-L-thyronine
(3,5-T2), a metabolite of the thyroid hormones (TH) thyroxine (T4) and triiodo-L-thyronine (T3), was reported to
cause beneficial health effects, including reversal of steatohepatosis and prevention of insulin resistance, in most
instances without adverse thyrotoxic side effects. However, the empirical evidence concerning the physiological
relevance of endogenously produced 3,5-T2 in humans is comparatively poor. Therefore, to improve the under-
standing of 3,5-T2-related metabolic processes, we performed a comprehensive metabolomic study relating serum
3,5-T2 concentrations to plasma and urine metabolite levels within a large general population sample.
Methods: Serum 3,5-T2 concentrations were determined for 856 participants of the population-based Study of
Health in Pomerania-TREND (SHIP-TREND). Plasma and urine metabolome data were generated using mass
spectrometry and nuclear magnetic resonance spectroscopy, allowing quantification of 613 and 578 metabolites in
plasma and urine, respectively. To detect thyroid function-independent significant 3,5-T2—metabolite associations,
linear regression analyses controlling for major confounders, including thyrotropin and free T4, were performed.
The same analyses were carried out using a sample of 16 male healthy volunteers treated for 8 weeks with 250lg/
day levothyroxine to induce thyrotoxicosis.
Results: The specific molecular fingerprint of 3,5-T2 comprised 15 and 73 significantly associated metabolites in
plasma and urine, respectively. Serum 3,5-T2 concentrations were neither associated with classical thyroid
function parameters nor altered during experimental thyrotoxicosis. Strikingly, many metabolites related to coffee
metabolism, including caffeine and paraxanthine, formed the clearest positively associated molecular signature.
Importantly, these associations were replicated in the experimental human thyrotoxicosis model.
Conclusion: The molecular fingerprint of 3,5-T2 demonstrates a clear and strong positive association of the serum
levels of this TH metabolite with plasma levels of compounds indicating coffee consumption, therefore pointing to
the liver as an organ, the metabolism of which is strongly affected by coffee. Furthermore, 3,5-T2 serum
concentrations were found not to be directly TH dependent. Considering the beneficial health effects of 3,5-T2
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administration observed in animal models and those of coffee consumption demonstrated in large epidemiological
studies, one might speculate that coffee-stimulated hepatic 3,5-T2 production or accumulation represents an
important molecular link in this connection.
Keywords: 3,5-diiodothyronine, metabolomics, caffeine metabolism, thyroid, thyrotoxicosis
Introduction
The classical thyroid hormones (TH) thyroxine (T4)and triiodothyronine (T3) represent key regulators of
development and metabolic homeostasis (1). In addition,
within the last two decades, considerable research efforts (2)
resulted in an expansion of the spectrum of metabolically
active TH metabolites, including 3-iodothyronamine (3) and
3,5-diiodo-L-thyronine (3,5-T2) (4). In hypothyroid rodent
models, 3,5-T2 was described to exert numerous beneficial
metabolic effects (4). Under high-fat diet conditions, ad-
ministration of 3,5-T2 prevented weight gain (5) and the
development of high-fat diet induced insulin resistance (6,7)
or even reversed hepatic steatosis (8–11).
Strikingly, it was reported that 3,5-T2 exerts these effects
independent of classical TH-signaling through nuclear re-
ceptors and hence without the well-known thyrotoxic side
effects on bone, heart, and the hypothalamus/pituitary/thy-
roid (HPT) axis. Consequently, 3,5-T2 was considered a
promising drug for the treatment of obesity and metabolic
syndrome. However, in particular, more recent animal stud-
ies (12,13) challenged this optimistic view by demonstrating
adverse consequences of dose-dependent 3,5-T2 treatment
such as an increased heart weight and suppression of the
HPT-axis (14–18). This confirmed the results of earlier
in vivo studies in rats that indicated differential liver stimu-
lating- and thyrotropin (TSH)-suppressing thyromimetic ef-
fects of 3,5-T2 compared with T3 (19).
Apart from these conflicting results from animal studies,
data on 3,5-T2 in humans are generally sparse. No con-
vincing translation of findings from animal models to hu-
mans has been presented yet. Administration of the 3,5-T2
synthetic analogue TRC150094 at a dose of 50mg/day for
4 weeks failed to improve lipid and glucose metabolic
homeostasis in volunteers presenting with an elevated
cardiometabolic risk (20). Studies in the 1980s reported an
age-dependent increase as well as sex-specific differences
in serum 3,5-T2 concentrations [3,5-T2], but no consistent
alterations in thyroid disease (21–26).
However, only recently the development of a novel im-
munoassay based on a monoclonal antibody against 3,5-T2
(27) enabled the precise and reliable determination of [3,5-
T2] in humans. Using this assay, no alterations in endogenous
[3,5-T2] with respect to the thyroid state in patient cohorts
were found (27), and even a population-based approach (28)
comprising more than 900 subjects revealed only moderate
associations with TSH and plasma glucose concentrations,
while the predicted inverse associations with blood lipid or
anthropometric parameters were not detected.
More detailed phenotyping of the same cohort was per-
formed by small-molecule content profiling of the urine sam-
ples using proton nuclear resonance (1H-NMR) spectroscopy.
This urine metabolomic approach revealed 3,5-T2-related al-
terations with respect to fatty acid oxidation or oxidative stress
that might provide links to observations in animal models
mentioned above (29). Strikingly, a strong positive association
of [3,5-T2] with urinary excretion of trigonelline raised par-
ticular interest as similar beneficial effects on glucose metab-
olism were described for both compounds (6,30–32).
To follow up on this notable observation, and to charac-
terize additional metabolic implications of 3,5-T2 among
humans, we substantially extended our previous 1H-NMR-
study by reanalyzing the same population-based cohort this
time using nontargeted as well as targeted metabolomic ap-
proaches and plasma samples in addition to urine. Serum TH
measurements that became available for the entire cohort
allowed us to test for TH-independent effects of 3,5-T2.
Materials and Methods
Study population
The Study of Health in Pomerania-TREND (SHIP-
TREND) is a population-based study recruited in Western
Pomerania, a rural region in northeastern Germany. A de-
tailed description of the study population and sampling pro-
cedure can be found elsewhere (33). In total, 4420 invited
subjects decided to participate in the study (50.1% response).
All participants gave written informed consent before par-
ticipation. The study was approved by the Ethics Committee
of the University of Greifswald and conformed to the princi-
ples of the Declaration of Helsinki. SHIP data are publicly
available for scientific purposes and can be applied for at
www.fvcm.med.uni-greifswald.de/dd_service/data_use_intro
.php?lang=ger.
For a subsample of 1000 participants, plasma and urine
metabolome data based on mass spectrometry (MS) and
NMR were available. Subjects with missing [3,5-T2] values
(n = 132) or potential confounders (n= 3), as well as subjects
reporting intake of medication influencing TH concentrations
(n = 9; amiodarone (ATC code C01BD01) or oral glucocor-
ticoids (ATC code H02AB), were excluded, resulting in a
final study sample of 856 subjects. For sensitivity analysis,
a euthyroid subpopulation was defined as follows: no intake
of thyroid-related medication (n= 86; ATC code H03A or
H03B) nor a TSH value outside the reference range [n = 100;
0.49mU/L < TSH <3.29mU/L (34)], thus leaving 690 indi-
viduals for the analysis (overlap between criteria existed).
Plasma metabolome data together with determined [3,5-
T2] and thyroid function parameters were further available
for a human model of experimental thyrotoxicosis, described
in detail earlier (35,36). Briefly, 16 healthy male volunteers
(ages 22–34 years) were treated with 250lg levothyroxine
(LT4) per day for 8 weeks. Plasma samples were repeatedly
collected every four weeks, including a restoration period of
eight weeks after completion of the treatment. Quantitative
plasmametabolome data were obtained fromMetabolon, Inc.
(Durham, NC) and included 349 metabolites in total.
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Laboratory measurements and phenotypic
characterization
Smoking status (current, former, or never smokers), daily
alcohol consumption, and physical activity (‡1 hour training
a week) were assessed using computer-aided personal inter-
views. Waist circumference was measured midway between
the lower rib margin and the iliac crest in the horizontal plane.
Fasting blood was sampled between 7.00 a.m. and 12.00 p.m.
in supine position from the cubital vein. During the same time
period, spot urine samples were collected. All samples were
either analyzed immediately or stored at -80C in the In-
tegrated Research Biobank (Liconic, Liechtenstein). Serum
concentrations of TSH, free T3 (fT3), and free T4 (fT4) were
measured using an immunoassay (Dimension VISTA; Sie-
mens Healthcare Diagnostics, Eschborn, Germany) with
functional sensitivities of 0.005mU/L, 0.77 pmol/L, and
1.3 pmol/L for TSH, fT3, and fT4, respectively. Determina-
tion of [3,5-T2] was performed using a monoclonal antibody-
based chemiluminescence immunoassay with a functional
sensitivity specified as 0.2 nM (27). The interassay variation
was between 5.6% and 12.9%. The working range was de-
clared as 0.2 to 10 nM 3,5-T2. More detailed information
about the assay has been reported previously (27,28).
Metabolome analysis
All metabolome measurement techniques are described in
detail in the Supplementary Data. Briefly, three different
approaches were combined as reported previously (37): (a)
nontargetedMS-based profiling of plasma and urine samples;
(b) targeted MS-based profiling of plasma samples using
the AbsoluteIDQ p180 Kit (BIOCRATES LifeSciences AG,
Innsbruck, Austria); and (c) NMR-based profiling of urine
samples.
After quality control and preprocessing (Supplementary
Data), data on 613 and 587 plasma and urine metabolites,
respectively, were available for statistical analyses. Of note,
some of these metabolites could not be identified unambig-
uously by assigning them to a defined chemical structure and
thus are subsequently referred with the notation ‘‘X’’ fol-
lowed by a unique number.
Statistical analyses
Linear regression models were applied to assess the as-
sociation between [3,5-T2] (independent variable) and plas-
ma as well as urine metabolites (dependent variable). Since
about one-third of the study population exhibited a [3,5-T2]
that was below the detection limit of the used assay (0.2 nM),
but clearly higher than blank values of the standard curve,
subjects were accordingly subdivided into three groups: [3,5-
T2] < 0.2 nM (N = 316), 0.2 < [3,5-T2] < 0.33 nM (N= 261),
and [3,5-T2] > 0.33 nM (N = 278). Subsequently, linear re-
gression analyses were performed using the defined group
variable as exposure. Furthermore, log-transformed [3,5-T2]
was used as exposure in the subpopulation with quantified
measurements. Models were adjusted for age, sex, waist
circumference, blood sampling time, as well as serum TSH
and fT4 concentrations. The latter enabled us to control for
potential confounding effects of thyroid function on the
presented associations.
Associations with TSH, fT3, and fT4 were tested using
linear regression following previous work (28), but addi-
tionally increasing the sample size from 64 (i.e., participants
with conspicuous TSH concentrations) to 856 participants
with available [3,5-T2] data. To account for the repeated
measurement character of the thyrotoxicosis study, we used
linear mixed effects models with [3,5-T2] as fixed effect
exposure and plasma metabolites as outcome. Dependency of
related samples, for example, repeated blood sampling on the
same individual, was incorporated as random effect and all
analyses were controlled for age, body mass index, and fT4
concentrations. The effect of LT4 treatment on [3,5-T2] was
tested using a Friedman ANOVA. Correction for multiple
testing was done using the Benjamini–Hochberg procedure,
controlling the false discovery rate at 5%. Multifluid data
were integrated using a Gaussian graphical model (GGM;
Supplementary Data) (38). Statistical analyses were carried
out using SAS version 9.4 (SAS statistical software, version
9.4; SAS Institute, Inc., NC) and R 3.3.2 (version 3.3.2; R
Foundation for statistical computing, Vienna, Austria).
Results
Characteristics of the study sample are summarized in
Table 1. Concerning sex-specific differences, TSH and fT4
concentrations were slightly but significantly lower among
men. As reported previously (27), no sex-specific dif-
ference in [3,5-T2] became apparent. Of special note, none
of the common thyroid function parameters was signif-
icantly associated with [3,5-T2] (Fig. 1) and, moreover,
[3,5-T2] was also unaltered during experimental LT4-
induced thyrotoxicosis (Fig. 1).
TH-independent association of [3,5-T2] with plasma
and urine metabolites
In total, [3,5-T2] was significantly associated with the
concentrations of 15 and 73 metabolites in plasma and urine,
respectively (Fig. 2). Notably, most of the associations
Table 1. General Characteristics of the Study
Population
Characteristics Men (N = 370) Women (N= 485) pa
Age, years 50.0 (39.0; 60.8) 51.0 (41.0; 61.0) 0.91
Smoking, %
Never 31.8 51.5 <0.01
Former 43.7 27.8
Current 24.3 20.6
Physical activity, %
>1 hour/week 27.8 25.4 0.46
<1 hour/week 72.2 74.6
Waist
circumference
94.0 (86.5; 102.3) 81.0 (74.0; 89.7) <0.01
Thyrotropin,
mU/L
1.12 (0.78; 1.50) 1.23 (0.83; 1.78) 0.01
fT4, pmol/L 13.1 (12.2; 14.2) 13.5 (12.5; 14.7) <0.01
fT3, pmol/L 4.97 (4.60; 5.31) 4.53 (4.23; 4.93) <0.01
3,5-T2, nM 0.25 (0.20; 0.39) 0.25 (0.20; 0.37) 0.94
Data are expressed as median (25th; 75th percentile).
aWilcoxon rank-sum test for continuous and v2-test for categor-
ical data were used for comparison.
3,5-T2, 3,5-diiodothyronine; eGFR, estimated glomerular filtra-
tion rate; fT3, free triiodothyronine; fT4, free thyroxine.
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became apparent in the comparison between the groups
of low (<0.20 nM) versus high (>0.30 nM) [3,5-T2]. Ex-
clusively positive associations were detected in plasma,
including those with 3-(4-hydroxyphenyl)lactate, the trypto-
phan metabolites indole lactate and kynurenine, trigonelline,
and the dipeptide cyclo(leu-pro).
Strikingly, the strongest [3,5-T2] associations were found
with metabolites related to caffeine metabolism, namely
caffeine, paraxanthine, theobromine, and theophylline (Fig. 2
and Table 2). For instance, the average caffeine levels in the
middle and the high [3,5-T2] groups were about 33% and
100% increased, respectively, compared with the lowest [3,5-
T2] group. Similarly, paraxanthine and theophylline levels in
plasma increased with 3,5-T2 concentrations in these groups
(Table 2). These findings were also reflected in the urine
metabolome where additionally significant positive [3,5-T2]
associations with the levels of 1,3,7-trimethylurate, 1,3-
dimethylurate, and 1,7-dimethylurate were revealed (Fig. 2).
Visual inspection of the derived metabolic network (GGM)
strongly supported the close interrelationship between those
metabolites (Fig. 3), which further comprised 5-acetylamino-
6-formylamino-3-methyluracil, the dipeptides cyclo(leu-pro)
in plasma and cyclo(gly-pro) in urine, as well as several
unknown compounds.
A second cluster of significantly positively [3,5-T2] asso-
ciated metabolites in urine comprised N-(2-furoyl)glycine,
ferulic acid 4-sulfate, as well as several unknown compounds.
Further positive associations were noted with the urine levels
of 5-oxoproline, N-acetyl phenylalanine, picolinate, sucrose,
3-methyluracil, cis-aconitate, as well as the benzoate me-
tabolites 3-methyl catechol sulfate and catechol sulfate. No-
tably, the [3,5-T2] association with urinary hippurate barely
missed the corrected statistical significance. Inverse associ-
ations were limited to urine levels of sulfated compounds
belonging to steroids, for example, dehydroisoandrosterone
sulfate or 21-hydroxypregnenolone sulfate (Fig. 2), pseu-
douridine, uracil, and five unknown compounds.
When the analyses were restricted to a euthyroid sub-
sample (Materials and Methods section), almost all associ-
ations remained significant. This included all primary
catabolites of caffeine as well as other surrogates of coffee
consumption such as trigonelline. The loss of few associa-
tions, including plasma kynurenine, indole lactate, and 3-(4-
hydroxyphenyl)lactate, as well as five unknown compounds
in urine, was most likely due to the resulting reduction in
statistical power rather than to a specific effect of thyroid
function since these associations initially reached statistical
significance only tightly below the applied threshold.
Further adjustment for plasma caffeine
To test whether the associations between [3,5-T2] and
metabolite levels were of distinct origin, we further adjusted
the linear models for the concentration of plasma caffeine as
the [3,5-T2] association with this metabolite was the stron-
gest in the present study. In consequence, all significant as-
sociations with [3,5-T2] were lost, with the sole exception of
plasma kynurenine levels in case of using [3,5-T2] as con-
tinuous exposure. Similarly, if our previous analyses (28)
were repeated with additional adjustment for plasma caf-
feine, significant associations were no longer observed either.
Replication of the main findings in a human model of
experimental LT4-induced thyrotoxicosis
Even under severe thyrotoxic conditions (mean TSH
<0.02mU/L and mean fT4> 28.6 pmol/L) after eight weeks
of LT4 treatment, no significant alterations in [3,5-T2] be-
came obvious ( p= 0.68; Fig. 1). Strikingly, the strong positive
associations between [3,5-T2] and central caffeine metabolites,
that is, caffeine, paraxanthine, 1,7-dimethylurate, and theoph-
ylline were replicated in this rather small study cohort (n= 16)
(Fig. 2 and Table 2).
Discussion
The primary aim of the present study was the detection of
clues for metabolic relevance of 3,5-T2 in humans by per-
forming association analyses between [3,5-T2] and the con-
centrations of plasma and urine metabolites, using available
comprehensive metabolome data in a relatively large
population-based and a smaller interventional human thyro-
toxicosis sample. Particularly, we searched for possible
thyroid function-independent effects that appeared plausible,
because previous studies did not reveal obvious associations
FIG. 1. (A–C) Predicted means from linear regression analyses with thyroid function parameters as exposure and [3,5-T2]
concentration as outcome in SHIP, either using the whole study population (solid) or a euthyroid subsample (dashed). (D)
Boxplots indicate time courses of [3,5-T2] measurements during an LT4 challenge for 8 weeks among 16 healthy male
volunteers [bas—baseline; w4(T4)/w8(T4)—four/eight weeks on 250 lg/day LT4; w12/w16–four/eight weeks after the LT4
application was finished]. Gray lines indicate individual time courses for the 16 volunteers. For none of the tested rela-
tionships, significant associations with [3,5-T2] could be detected. 3,5-T2, 3,5-diiodothyronine; LT4, levothyroxine. Color
images are available online.
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FIG. 2. Heat map based on cor-
rected p-values (controlling the
FDR at 5%) from linear regression
analyses using either tertiles of 3,5-
diiodothyronine (3,5-T2; <0.20 nM,
0.20–0.33 nM, >0.33 nM) or
log(3,5-T2) concentrations as ex-
posure and plasma and urine me-
tabolites as outcome. Models were
adjusted for age, sex, waist cir-
cumference, time of blood sam-
pling, and thyrotropin and fT4
concentrations. Columns indicate
the effect comparing with the
lowest 3,5-T2 group or results from
linear regression using log(3,5-T2).
Orange and blue shadings indicate
positive and inverse associations,
respectively. Thick frames indicate
significant (FDR <0.05) associa-
tions. Analyses were performed on
the whole sample as well as a eu-
thyroid subsample. LT4 treat = as-
sociations between 3,5-T2 and
named metabolites in an LT4
challenge; models were adjusted
for age, sex, BMI, and fT4 con-
centrations. Corresponding estima-
tes and FDR values are given in
Table 2. *Linear regression analy-
ses were only performed including
participants with 3,5-T2 values
above 0.20 nM. FDR, false dis-
covery rate; fT4, free thyroxine.
Color images are available online.
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between the concentrations of 3,5-T2 and those of T4 or T3
(27,28,39–41). These were expected as it was hypothesized
that classical TH might represent direct precursors for 5¢-
deiodinase-mediated 3,5-T2 formation. Furthermore, 3,5-T2
was not found to be produced by the thyroid gland itself (42).
The results presented here indicate a clear link between
[3,5-T2] and coffee metabolism as reflected by the associated
metabolites. This relationship was also observed in the ex-
perimental thyrotoxicosis model, confirming that [3,5-T2] is
not primarily determined by circulating TH concentrations
and therefore does not reflect the actual thyroid functional
state.
The metabolomic fingerprint of 3,5-T2 is not thyroid
function dependent
Despite numerous results from animal studies revealing
complementary effects of 3,5-T2 to classical TH, there is still
ongoing debate about the major site(s) and mode of 3,5-T2
synthesis and its physiological relevance in humans. Detec-
tion of 3,5-T2 in the circulation of thyroidectomized patients
treated with LT4 demonstrated extrathyroidal conversion of
classical TH to 3,5-T2 (27). However, our results strongly
argue against a simple thyroid function- and TH dose-
dependent [3,5-T2] production. First, no significant associa-
tions with circulating TH were detected as expected in the
case of constant rate conversion of TH to 3,5-T2. Strikingly,
in the present study, these were missing in the population-
based cohort as well as the thyrotoxic individuals. While
these findings partially contrast with our previous results on
the interrelationship of TSH with [3,5-T2] in human serum,
they are in line with negative reports on a simple TH
dependency of [3,5-T2] (22,27).
Second, the metabolomic 3,5-T2 fingerprint, especially the
main signature of caffeine-related metabolites, was quite
different from those described for thyroid diseases or circu-
lating TH (36,43–46). The fingerprint of TH in plasma is
dominated by lipid species, c-glutamyl dipeptides, and shifts
in amino acid proportions (47). Merely for the urine meta-
bolome, a small overlap between the fingerprints of 3,5-T2
and classical TH was observed, as hippurate and trigonelline
were also associated with the TSH and fT4 serum concen-
trations, respectively, in population-based studies (43,48).
While several animal studies (14–16,19) reported dose-
dependent thyromimetic effects of 3,5-T2 on the HPT-axis
and the heart (4), such supraphysiological concentrations in
the circulation required to exert these adverse effects were
most probably not reached in our study samples. Never-
theless, we cannot rule out that endogenous 3,5-T2 affects the
HPT-axis, but the independence of the metabolomic 3,5-T2
fingerprint from TSH and fT4 concentrations in our two study
cohorts strongly argues for a metabolic fate of 3,5-T2 distinct
from that of the classical TH.
3,5-T2 is interrelated with the metabolism
of coffee ingredients
The strongest associations with [3,5-T2] were detected for
caffeine and its direct catabolites (49), for example, para-
xanthine, theophylline, and 1-methylxanthine, in plasma as
FIG. 3. (A) Subnetwork of the derived metabolic network (estimated by Gaussian graphical modeling) emphasizing caffeine
and related compounds. On each node, the results from linear regression analysis for 3,5-T2 concentration either as categorical
(effect compared with the lowest group, that is, <0.20 nM; dark gray: 0.20–0.33 nM and light gray: >0.33 nM) or continuous
variable (*considering participants with [3,5-T2] >0.20 nM; black) as portion of the association strength are given as -log10
(FDR-value). Significant results in at least one of these with an FDR value below 5% are depicted as pie charts. Node sizes are
inversely proportional to the lowest FDR-value. The prefixes P and U denote plasma and urine metabolites, respectively. Edges
represent significant partial correlations (par. cor.) between metabolites. (B) Boxplots of plasma (blank) or urine (gray) levels
of caffeine and paraxanthine across groups of [3,5-T2]. Diamonds indicate mean levels.
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well as urine. Furthermore, numerous metabolites related to
coffee consumption were positively associated with [3,5-T2]
in plasma and/or urine, including trigonelline present in green
coffee that passes through the body without undergoing
substantial phase II metabolism (49), N-(2-furoyl)glycine
metabolized from furan derivatives present in coffee products
(50), and the proline-based diketopiperazine cyclo(leu-pro)
generated in the roasting process, which contributes to the
bitter taste of coffee (51). These associations were also ob-
served under the conditions of experimental thyrotoxicosis.
While these results strongly argue for a causative relationship
between coffee consumption and [3,5-T2], this interpreta-
tion, because based exclusively on association findings, has
nevertheless to be treated with appropriate caution.
Known effects of coffee on hepatic
detoxification systems
The central question arising from these results concerns
the physiological mechanisms underlying the observed as-
sociations. Potential explanations outlined below are based
on the fact that the liver, the most important detoxification
organ of the human body, is strongly affected by coffee.
Transcriptional induction by coffee was demonstrated for
the regulon controlled by the transcription factor aryl hydro-
carbon receptor (AHR) using hepatic cell lines and livers of a
humanized murine model (52). The AHR is a nuclear receptor
that after activation by multiple endogenous and exogenous
ligands (53) translocates to the nucleus, dimerizes with the
AHR nuclear translocator protein, subsequently binds to xe-
nobiotic response elements, and induces expression of a large
regulon. Hepatic murine transcriptome analyses identified
several 100 AHR target genes (54), where many of the en-
coded proteins are involved in xenobiotic metabolism (53).
Among the AHR target genes in humans as well as mice is
NFE2L2 encoding NRF2, the master regulator of another
major cellular defense system against oxidative and other
cytotoxic stress (55). After nuclear translocation, NRF2 binds
to antioxidant response element enhancer sequences located
in promoters of many genes encoding proteins necessary for
electrophile detoxification (56). Consequently, AHR regulon
induction also causes transcriptional activation of the NRF2
regulon comprising more than 200 genes as indicated by
transcriptome analyses, including genes encoding proteins
involved in protection against oxidative stress and multidrug
response transporters (56,57).
Thus, extensive transcriptional reprogramming of the liver
resulting in altered enzyme and transporter expression ap-
pears to be caused by (chronic) coffee consumption. Of note,
as transcriptional upregulation of AHR target genes is also
mediated by decaffeinated coffee, other coffee ingredients
than caffeine are responsible for initial activation of the AHR
regulon [44].
Beneficial health effects of coffee consumption
In summary, the strong hepatic activation of the cytopro-
tective and genoprotective AHR and NRF2 systems by coffee
suggests to cause increased detoxification and elimination of
xenobiotics, oxidative intermediates, and reactive oxygen
species generated by phase I metabolism is in line with the
beneficial health effects of moderate coffee consumption that
were observed in many large epidemiological studies and are
today beyond controversy. For example, a multinational co-
hort study analyzing data of a sample of 521,330 individuals
detected a reduced risk for death from various causes asso-
ciated with coffee consumption (58). In particular, coffee
consumption is associated with a decreased risk of several
chronic diseases, including type 2 diabetes (T2D), cardio-
vascular disease (CVD), and cancer, as well as neurode-
generative conditions such as Parkinson’s disease (49).
Mechanistically, coffee-mediated activation of the AHR
and NRF2 regulons enhances the general detoxification ca-
pacity of the liver and in particular the potential in neutrali-
zation of reactive oxygen species. Upregulation of the
synthesis of the key enzyme of glutathione (GSH) synthesis,
hepatic c-glutamylcysteine synthetase, the most important
site of GSH synthesis and storage (59), explains increased
GSH concentrations in plasma (60,61) and colorectal mucosa
(60) observed after daily coffee consumption. Indeed, a
systemic and organ-specific improvement of the detoxifica-
tion capacity might explain the reduced cancer risk associ-
ated with coffee consumption, as well as the significant
inverse association between moderate coffee drinking and
CVD risk (62).
In case of T2D, a lower risk of coffee drinkers to develop the
disease was demonstrated in several studies (63–65). As
chronical oxidative stress triggers the development of T2D
(66), coffee-mediated activation of corresponding protection
systems might contribute to this observed risk reduction.
However, another well-defined effect of coffee might be even
more important, namely its impressive potential to reduce the
hepatic fat content: there is a strong epidemiological associa-
tion between T2D and hepatic steatosis, and several common
models on the pathogenesis of insulin resistance and, subse-
quently, T2D include the development of a fatty liver as key
event [e.g., (67)]. Notably, epidemiological evidence also in-
dicates that coffee consumption reduces the hepatic fat content
(68,69), as well as liver enzyme serum activities (58). There-
fore, hepatic fat reduction is suggested to be a crucial factor in
lowering T2D risk by coffee consumption.
The underlying mechanism is, however, not yet fully un-
derstood. Although stimulation of intrahepatic lipolysis and
fatty acid oxidation via caffeine-induced flux through an
autophagy/lysosomal pathway was demonstrated in a murine
model (70), human intervention studies revealed only small
effects on weight reduction and fat metabolism (71). Fur-
thermore, of particular importance, the inverse relationships
between coffee consumption and T2D reported in Refs. (72)
and (65) were observed for caffeinated as well as decaf-
feinated coffee.
Effects of TH and their derivatives on liver fat catabolism
Of particular relevance in the context of the present study,
TH are known to reduce the hepatic triglyceride content, via
stimulation of lipophagy of intracellular lipid droplets (73), as
well as transcriptional induction of CPT1 encoding carnitine
palmitoyltransferase-I, a direct target of TH-activated TH
receptor a and b (TR) (74). Induction of hepatic CPT1 ex-
pression causes intensified mitochondrial b-oxidation and,
consequently, fat burning. In addition, activation of the citrate
cycle is ensured by TH-mediated transcriptional upregulation
of IDH3A encoding the a-subunit of mitochondrial NAD+-
dependent isocitrate dehydrogenase 3 (75–77). Therefore,
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TH agonists could principally represent promising drugs for
the treatment of hepatic steatosis and obesity-related dis-
eases, but harmful effects of the studied agonists on heart,
bone, and muscle have, so far, prevented their use as ther-
apeutic compounds (18,78).
Of special interest in relation to the present work, the an-
tihepatosteatotic potential of TH as well as its unwanted ef-
fects in other organs applies not only to the classical TH but
also for their metabolite 3,5-T2 (4–13,18), as outlined in the
Introduction section. In particular, the characteristics of 3,5-
T2 motivated our association study to get further information
on its putative physiological role.
Hypothetical explanations for the association between
[3,5-T2] and coffee metabolites
Considering the described interrelationships between T2D,
hepatic steatosis, the protective effects of coffee consumption
on these disease entities, as well as its strong impact on he-
patic metabolism via activation of the AHR-NFR2 system,
and the significant potential of classical TH and 3,5-T2 to
reduce liver fat and induce drug-metabolizing enzymes (13),
one might hypothesize that the observed association between
[3,5-T2] and coffee metabolites reflects the intrahepatic
physiological state, thereby indicating coffee-induced 3,5-T2
production and accumulation with proportional excretion
into the circulation.
According to this model, one or more coffee compounds
aside from caffeine may induce the AHR-NRF2 axis, where
the subsequent extensive hepatic gene expression repro-
gramming, by an unidentified molecular mechanism, medi-
ates an increase in the hepatic 3,5-T2 concentrations. This
could be accomplished either via stimulated generation, for
example, by enhanced deiodination of TH or reduced ca-
tabolism of 3,5-T2. By activation of the liver-dominating
TRb and transcriptional upregulation of the corresponding
regulon, the increased intrahepatic 3,5-T2 concentrations
could subsequently stimulate the hepatic fat catabolism
mechanisms. The resulting reduction in hepatic fat content
might finally reduce the risk for hepatic steatosis and sec-
ondary disorders, a concept that is consistent with the re-
ported epidemiological findings.
Of course, other explanations are conceivable: for in-
stance, the coffee-mediated activation of the AHR-NFR2
system could induce expression of one or more hepatic 3,5-
T2 exporter proteins, which would also explain the observed
associations. However, the possibility of a putative key role
of endogenous 3,5-T2 in hepatic metabolism should en-
courage further specific animal model-based experiments to
clarify the mechanism explaining the observed association
between [3,5-T2] and coffee metabolites. The fact that this
finding represents the first clear association between [3,5-T2]
and a physiologically relevant trait in a larger human study
sample emphasizes the potential of nontargeted OMIC
studies to increase the understanding of complex physio-
logical relationships.
Strengths and limitations
A clear strength of the present study consists in the
availability of both large-scale metabolome data and classical
measures of thyroid function that allows to derive informa-
tion on the specific metabolic fate of 3,5-T2, where the en-
dogenous role of the latter in humans is still unclear.
Furthermore, the observed associations between [3,5-T2] and
coffee metabolites do not rely on self-reported coffee con-
sumption as in many epidemiological studies, but on mea-
sured concentrations of specific ingredients of coffee in
plasma and urine samples. However, given that these data are
based on associations, the results are of observational nature
and required in part transformation and statistical evaluation
of the comprehensive metabolomic data sets; therefore, the
data do not allow to assume a causal relationship. For these
reasons, appropriate animal model-based intervention studies
or a coffee-ingestion trial in humans is required to test these
hypotheses.
In conclusion, using state-of-the-art metabolic profiling to
analyze plasma and urine samples of a larger human study
population, we were able to detect a novel connection between
serum 3,5-T2 concentrations and coffee metabolism. The hy-
pothetical mechanisms, that is, that coffee-induced in-
trahepatic accumulation of 3,5-T2 initiates liver fat reduction
via activation of TR-dependent transcriptional regulation,
have to be tested in appropriate experimental model systems.
In addition, we were able to demonstrate that serum 3,5-T2
concentrations are widely independent from the classical pa-
rameters of thyroid function, that is, TSH, fT4, and fT3.
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